OncoMatch/Clinical Trials/NCT06225921
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
Is NCT06225921 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Adebrelimab and Dalpiciclib 100mg for esophageal squamous cell carcinoma.
Treatment: Adebrelimab · Dalpiciclib 100mg · Dalpiciclib 150mg — The purpose of this study is to explore the safety and feasibility of anti-programmed cell death ligand 1(PD-L1) immunotherapy, Adebrelimab, combined with cyclin-dependent kinase 4/6 blockade, Dalpiciclib, as a new neoadjuvant treatment regimen for patients with resectable esophageal squamous cell carcinoma (ESCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Currently undergoing other chemotherapy
Cannot have received: radiotherapy
Currently undergoing other...radiotherapy
Cannot have received: targeted therapy
Currently undergoing other...targeted therapy
Cannot have received: immunotherapy
Currently undergoing other...immunotherapy
Cannot have received: investigational drug
Received any investigational drug within 4 weeks prior to the first dose
Lab requirements
Cardiac function
No grade II and above cardiac dysfunction (NYHA criteria), ischemic heart diseases, etc.
Presence of serious medical diseases, such as grade II and above cardiac dysfunction (NYHA criteria), ischemic heart diseases, etc.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify